494 related articles for article (PubMed ID: 32659438)
1. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
Liu R; Lin J; Li P
Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
[TBL] [Abstract][Full Text] [Related]
2. TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.
Li P; Liu R; Lin J; Ji Y
J Biopharm Stat; 2020 Nov; 30(6):979-992. PubMed ID: 32951518
[TBL] [Abstract][Full Text] [Related]
3. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
Takahashi A; Suzuki T
Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
[TBL] [Abstract][Full Text] [Related]
4. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
Koopmeiners JS; Modiano J
Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
[TBL] [Abstract][Full Text] [Related]
5. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
6. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.
Guo W; Wang SJ; Yang S; Lynn H; Ji Y
Contemp Clin Trials; 2017 Jul; 58():23-33. PubMed ID: 28458054
[TBL] [Abstract][Full Text] [Related]
8. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
Guo B; Li Y
BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
[TBL] [Abstract][Full Text] [Related]
9. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
Zhou Y; Lee JJ; Yuan Y
Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
[TBL] [Abstract][Full Text] [Related]
10. Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors.
Chen X; Zhang J; Jiang Q; Yan F
J Biopharm Stat; 2022 Jan; 32(1):34-52. PubMed ID: 35594366
[TBL] [Abstract][Full Text] [Related]
11. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Guo B; Li Y
Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
[TBL] [Abstract][Full Text] [Related]
12. CFO: Calibration-free odds design for phase I/II clinical trials.
Jin H; Yin G
Stat Methods Med Res; 2022 Jun; 31(6):1051-1066. PubMed ID: 35238697
[TBL] [Abstract][Full Text] [Related]
13. On the relative efficiency of model-assisted designs: a conditional approach.
Lin R; Yuan Y
J Biopharm Stat; 2019; 29(4):648-662. PubMed ID: 31258039
[TBL] [Abstract][Full Text] [Related]
14. Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials.
Ananthakrishnan R; Green S; Li D; LaValley M
Contemp Clin Trials Commun; 2018 Jun; 10():62-76. PubMed ID: 29696160
[TBL] [Abstract][Full Text] [Related]
15. Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ET.
Zhao Y; Liu R; Takeda K
Pharm Stat; 2023; 22(3):440-460. PubMed ID: 36514849
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS).
Pan H; Xie F; Liu P; Xia J; Ji Y
Clin Trials; 2014 Feb; 11(1):49-59. PubMed ID: 24137041
[TBL] [Abstract][Full Text] [Related]
17. Comparison of design methods for a safety run-in phase of a phase II clinical trial.
Ji L; Alonzo TA
Clin Trials; 2023 Apr; 20(2):181-191. PubMed ID: 36628921
[TBL] [Abstract][Full Text] [Related]
18. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
Takeda K; Taguri M; Morita S
Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
[TBL] [Abstract][Full Text] [Related]
19. Small-sample behavior of novel phase I cancer trial designs.
Oron AP; Hoff PD
Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
[TBL] [Abstract][Full Text] [Related]
20. A novel Bayesian seamless phase I/II design.
Pan H; Huang P; Wang Z; Wang L; Li C; Xia J
PLoS One; 2013; 8(9):e73060. PubMed ID: 24023809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]